Dr. Chintakuntlawar is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
13400 E Shea Blvd
Scottsdale, AZ 85259Phone+1 480-301-8000
Education & Training
- Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Hematology and Medical Oncology, 2012 - 2016
- University of Arkansas for Medical Sciences (UAMS) College of MedicineResidency, Internal Medicine, 2009 - 2012
- Grant Medical CollegeClass of 2003
Certifications & Licensure
- AZ State Medical License 2024 - 2025
- MN State Medical License 2012 - 2025
Clinical Trials
- hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of Relapse Start of enrollment: 2014 Dec 01
- Lenvatinib in Treating Patients With Metastatic or Advanced Pheochromocytoma or Paraganglioma That Cannot Be Removed by Surgery Start of enrollment: 2017 May 31
Publications & Presentations
PubMed
- Pemetrexed-carboplatin salvage therapy in advanced thyroid cancers.Kenzie K Lee, John C Morris 3rd, Aditi Kumar, Ashish V Chintakuntlawar, Candy Peskey
Head & Neck. 2024-10-27 - Low testing rates and highprevalence: Poly (ADP-ribose) polymerase inhibitor use in Middle East/homologous recombination deficiency-positive cancer patients.Naveed Syed, Ashish Vittalrao Chintakuntlawar, Deepti Vilasini, Aisha Mohamed Al Salami, Riad Al Hasan
World Journal of Clinical Oncology. 2024-07-24 - Racial Disparities in Cardiovascular and Cerebrovascular Adverse Events in Patients with Non-Hodgkin Lymphoma: A Nationwide Analysis.Kanishka Uttam Chandani, Siddharth Pravin Agrawal, Maharshi Raval, Sajid Siddiq, Ahmed Nadeem
Medicina. 2024-05-11
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: